SCHEMBL3811264

SCHEMBL3811264

CC(=O)c1ccccc1Nc1nc(Cl)ncc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 5/20 0.54
MAPK10 P53779 4/20 0.50
MAPK9 P45984 3/20 0.50
IGF1R P08069 2/20 0.49
ALK Q9UM73 3/20 0.47
GSK3B P49841 2/20 0.47
CDC7 O00311 1/20 0.47
DAPK3 O43293 1/20 0.47
JAK2 O60674 1/20 0.47
ROCK2 O75116 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47
PIM1 P11309 1/20 0.47
PRKACA P17612 1/20 0.47
CDK2 P24941 1/20 0.47
SYK P43405 1/20 0.47
CSNK1A1 P48729 1/20 0.47
CDK8 P49336 1/20 0.47
CLK2 P49760 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29900878 0.87 ULK1 (0.58) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL375665 0.87 ULK1 (0.58) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL2061282 0.86 ULK1 (0.56) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL30421641 0.86 ULK1 (0.56) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL13809933 0.84 ALK (0.43) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL375921 0.84 MAPK8 (0.49) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL31174579 0.84 MAPK8 (0.49) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL17194046 0.83 MAPK10 (0.52) MAPK8MAPK10MAPK9IGF1RALK
SCHEMBL5563903 0.81 CDC7 (0.55) MAPK8MAPK10MAPK9GSK3BCDC7
SCHEMBL1204025 0.81 MAPK8 (0.48) MAPK8MAPK10MAPK9IGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1597251-B1 PYRIMIDINE COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-06-10 EP disclosed
US-7514446-B2 Pyrimidine compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-04-07 US disclosed
US-7514446-B2 Pyrimidine compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-04-07 US disclosed
US-7514446-B2 Pyrimidine compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-04-07 US disclosed
US-20070010668-A1 Pyrimidine compounds NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-01-11 US disclosed
US-20070010668-A1 Pyrimidine compounds NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-01-11 US disclosed
US-20070010668-A1 Pyrimidine compounds NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-01-11 US disclosed
EP-1597251-A2 PYRIMIDINE COMPOUNDS SmithKline Beecham Corporation (US) 2005-11-23 EP disclosed
WO-2004074244-A2 PYRIMIDINE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010668-A1 Pyrimidine compounds TYMS, TYMP, DPYD MAPK8 3281/4885MAPK10 3487/4885MAPK9 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.